Veracyte, INC 10-Q quarterly reports

Veracyte, Inc. announced its Q2 2026 financial results, showcasing a significant increase in total revenue driven by robust testing revenue, alongside strategic advancements in its diagnostic platforms.

Veracyte, Inc. announced a significant increase in revenue and net income for the first quarter of 2026, driven by strong performance in its testing business.

Veracyte, Inc. reported a significant increase in net income and testing revenue for the third quarter and first nine months of 2025, driven by higher diagnostic test volumes.

Veracyte, Inc. reported a 14% increase in total revenue for the second quarter of 2025, reaching $130.2 million, despite a net loss of $1.0 million primarily due to a $20.5 million asset impairment charge related to its French subsidiary divestiture.

Veracyte's Q1 2025 revenue increased by 18% year-over-year, driven by growth in testing revenue and biopharmaceutical collaborations.

Veracyte's Q3 2024 results show significant growth in testing revenue and a return to profitability, despite some challenges in product and biopharmaceutical revenue.

Veracyte, Inc. reports a profitable second quarter of 2024, driven by a significant increase in testing revenue and overall revenue growth.

Veracyte's first quarter of 2024 saw a significant increase in testing revenue, offsetting declines in other areas and resulting in a smaller net loss compared to the same period last year.